| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity ML Broz, M Binnewies, B Boldajipour, AE Nelson, JL Pollack, DJ Erle, ... Cancer cell 26 (5), 638-652, 2014 | 1176 | 2014 |
| RNA-binding protein Dnd1 inhibits microRNA access to target mRNA M Kedde, MJ Strasser, B Boldajipour, JAFO Vrielink, K Slanchev, ... Cell 131 (7), 1273-1286, 2007 | 884 | 2007 |
| Control of chemokine-guided cell migration by ligand sequestration B Boldajipour, H Mahabaleshwar, E Kardash, M Reichman-Fried, ... Cell 132 (3), 463-473, 2008 | 707 | 2008 |
| Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells JJ Engelhardt, B Boldajipour, P Beemiller, P Pandurangi, C Sorensen, ... Cancer cell 21 (3), 402-417, 2012 | 346 | 2012 |
| A role for Rho GTPases and cell–cell adhesion in single-cell motility in vivo E Kardash, M Reichman-Fried, JL Maître, B Boldajipour, E Papusheva, ... Nature cell biology 12 (1), 47-53, 2010 | 283 | 2010 |
| Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma C Sommer, B Boldajipour, TC Kuo, T Bentley, J Sutton, A Chen, T Geng, ... Molecular therapy 27 (6), 1126-1138, 2019 | 121 | 2019 |
| Adaptive immune regulation of mammary postnatal organogenesis V Plaks, B Boldajipour, JR Linnemann, NH Nguyen, K Kersten, Y Wolf, ... Developmental cell 34 (5), 493-504, 2015 | 103 | 2015 |
| Killing the messenger: The role of CXCR7 in regulating primordial germ cell migration H Mahabaleshwar, B Boldajipour, E Raz Cell adhesion & migration 2 (2), 69-70, 2008 | 60 | 2008 |
| Cxcl12 evolution–subfunctionalization of a ligand through altered interaction with the chemokine receptor B Boldajipour, M Doitsidou, K Tarbashevich, C Laguri, SR Yu, J Ries, ... Development 138 (14), 2909-2914, 2011 | 47 | 2011 |
| Chimeric antigen receptors targeting B-cell maturation antigen TCC Kuo, BA Boldajipour, JFC Riggers, P Duchateau, R Galetto, ... US Patent 10,294,304, 2019 | 41 | 2019 |
| What is left behind—quality control in germ cell migration B Boldajipour, E Raz Science's STKE 2007 (383), pe16-pe16, 2007 | 38 | 2007 |
| A versatile safeguard for chimeric antigen receptor T-cell immunotherapies J Valton, V Guyot, B Boldajipour, C Sommer, T Pertel, A Juillerat, ... Scientific reports 8 (1), 8972, 2018 | 36 | 2018 |
| Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine B Boldajipour, A Nelson, MF Krummel JCI insight 1 (20), 2016 | 36 | 2016 |
| Direct control of CAR T cells through small molecule-regulated antibodies S Park, E Pascua, KC Lindquist, C Kimberlin, X Deng, YSL Mak, Z Melton, ... Nature Communications 12 (1), 710, 2021 | 33 | 2021 |
| ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for the treatment of multiple myeloma C Sommer, B Boldajipour, J Valton, R Galetto, T Bentley, J Sutton, Y Ni, ... Blood 132, 591, 2018 | 14 | 2018 |
| Preclinical evaluation of allogeneic anti-bcma chimeric antigen receptor t cells with safety switch domains and lymphodepletion resistance for the treatment of multiple myeloma B Boldajipour, R Galetto, C Sommer, T Pertel, J Valton, Y Park, ... Blood 128 (22), 381, 2016 | 11 | 2016 |
| Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors AM Metelo, A Jozwik, LA Luong, D Dominey-Foy, C Graham, C Attwood, ... Cancer Research Communications 2 (3), 158-171, 2022 | 10 | 2022 |
| Design and validation of inducible TurboCARs with tunable induction and combinatorial cytokine signaling RJ Lin, AR Nager, S Park, J Sutton, C Lay, Z Melton, Y Zhang, ... Cancer Immunology Research 10 (9), 1069-1083, 2022 | 6 | 2022 |
| LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors S Park, C Simianer, S Spadinger, X Wang, P Sundar, S Potluri, R Lynn, ... Cancer Research 82 (12_Supplement), 2754-2754, 2022 | 4 | 2022 |
| Allogeneic anti-Bcma CAR-T cells show tumour specific killing against primary multiple myeloma cells from different genomic sub-groups AM Metelo, I Walker, A Jozwik, C Graham, C Attwood, K Sanchez, ... Blood 134, 1834, 2019 | 4 | 2019 |
